Preparing stock dashboard...
Preparing stock dashboard...
4178.TW - Taiwan - Healthcare - Biotechnology
StemCyte International, Ltd., a biotechnology company, develops cord bloodbased cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-related conditions, and metabolic disorders, as well as for post-covid, acute stroke, and cerebral palsy. Further, it develops CB201(CB-NK), an API in preclinical development for the treatment of hematological malignancies. The company was founded in 1997 and is based in Taipei, Taiwan. StemCyte International, Ltd. operates as a subsidiary of Diamond Biofund Inc.
Data updated June 17, 2026
| Metric | Value ('000,000) |
|---|
Latest period compared with the previous period and the matching prior-year period.
Loading financial changes...
Scores this stock using the same metrics model as the compare page.
| Metric | Value | Score |
|---|
Calculated locally from stored daily price and volume history.
Loading technical analysis...
Mouse wheel or pinch to zoom. Drag chart to pan. Double-click to reset zoom.